KUALA LUMPUR (March 19): ACE Market-bound Alpha IVF Group Bhd posted a net profit of RM12.21 million for the second quarter ended Nov 30, 2023 (2QFY2024), on the back of revenue of RM38.54 million.
In a bourse filing on Monday, the company said the revenue was derived mainly from the provision of assisted reproductive services focusing on in-vitro fertilisation (IVF) treatments.
As the company is not yet a public listed entity, there are no comparative figures for the same period in the previous year.
Earnings per share stood at 0.27 sen.
For the cumulative six months ended Nov 30, 2023, Alpha IVF said it posted a net profit of RM25.34 million, on the back of revenue of RM80.14 million.
In a separate statement, Alpha IVF group managing director Datuk Dr Colin Lee Soon Soo said the 2QFY2024 financial performance highlights the group’s ability to ride the wave of medical tourism and growing need for IVF treatments.
“Our positive financial performance, along with our imminent listing and enhanced profile in the public eye, allows us to capitalise on new market opportunities.
“We will continue to put our growth plans in motion, including expanding our business locally and regionally, and simultaneously addressing the burgeoning demand,” he said.
Alpha IVF is scheduled to be listed on the ACE Market on March 22, at an issue price of 32 sen.
Read also:
Public portion of Alpha IVF's IPO oversubscribed by 1.73 times
Alpha IVF starts taking orders from investors for up to RM466.5m IPO
Alpha IVF signs underwriting agreement for largest ever ACE Market IPO
Fertility care specialist Alpha IVF gets Bursa nod for IPO, expects to list on ACE Market within 1Q
Fertility care specialist Alpha IVF plans ACE Market listing to set up new medical centres